3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
32
Lung Neoplasms
11
Brain Neoplasms
5
Meningeal Carcinomatosis
2
Recurrence
1
Rare Tumor
1
Radiation Pneumonitis
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
1
NSCLC
1
Liver Diseases
1
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
1
Digestive System Diseases
1
Carcinoma
1
Aumolertinib
1
Advanced Non-small Cell Lung Cancer
1
Adenocarcinoma
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
aumolertinib
×
Clear all
NCT04401059
2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4
Unknown
744 enrolled